Feedback, the AIM-quoted clinical software company behind the Bleepa platform, published final results on 6 November 2026 that showed a narrower operating loss but a sharp fall in cash. The directors reported a material uncertainty over the company's ability to continue as a going concern. They said new contracts or fresh funding would be needed, and that without new contracts the cash runway would last only until the end of the first quarter of 2027.
What the company does
Feedback develops digital health technology for the NHS. Its main product, Bleepa, is a clinical communication and care pathway platform that lets clinicians share information, including medical images, and manage patients along defined pathways. The company has been working on care pathways that move patients away from traditional outpatient appointments. In an update in July 2026, it said 100% of breathlessness patients on a Sussex pathway had been diverted from outpatient appointments, and that an insomnia pathway had been rolled out across Kent, Surrey and Sussex.
Latest developments
In a Business update on 29 October 2026, Feedback said a contract extension with Queen Victoria Hospital, worth £127,000, would run until March 2027. It also said the Surrey and Sussex integrated care board had provided an extra £249,000 to fund further development of Bleepa. The company added that it was exploring a multi-year elective care transformation opportunity with a large integrated care board. This could begin with a paid pilot, followed by wider commissioning from April 2027.
Earlier in the year, Feedback said it was pursuing a national contract opportunity with NHS England, with a decision expected by the end of 2026. It also reported technical progress, including a new version of Bleepa and integrations with the NHS e-Referral Service, Patients Know Best and an electronic medical record system.
Financial and Dividend picture
For the year to 31 May 2026, Revenue was £0.78m, down from £0.89m, while total sales were £0.94m, with Bleepa accounting for 91%. Gross Margin fell to 79% from 88%. The operating loss before interest and tax narrowed to £3.24m from £4.21m, and the EBITDA loss was £2.99m, compared with £3.06m. The loss per share was 7.96p, and the results included an Impairment of intangible assets of £0.31m.
Cash at 31 May 2026 was £2.73m, down from £5.95m a year earlier. Feedback does not pay a dividend, and given its losses and funding needs, none should be expected in the near term.
Sector and index context
Feedback is one of several small digital health companies in the FTSE AIM All Share Index trying to win business from the NHS. The NHS has been looking for ways to reduce waiting lists and manage elective demand, which creates opportunities for pathway technology. However, NHS procurement can be slow, and decisions often depend on central or regional budgets, which makes revenue timing hard to predict for small suppliers.
Key risks
The most immediate risk is funding. If expected contracts are delayed or not won, the company is likely to need to raise money, which could dilute existing shareholders, or take other measures. Revenue remains small relative to costs, and the business depends heavily on a few NHS customers and on the outcome of larger commissioning decisions.
What to watch next
The key milestones are the NHS England national contract decision, which the company expected by the end of 2026, and progress on the elective transformation opportunity with a large integrated care board. Investors will also watch for any fundraising announcement and the outcome of the Annual General Meeting notified alongside the final results.
_11_19_2026_14_04_21_792016.jpg)
_11_19_2026_14_04_28_358813.jpg)




Please wait processing your request...